



Aspirational Best Practice Clinical Pathway for the Management of Oesophageal Carcinoma

WMCN Oesophageal Carcinoma Pathway June 2016. These timings are currently aspirational and are an attempt to see what resources are required to comply with the new 2020 NHS cancer targets.

Reviewed by: Upper GI Expert Advisory Group – 29 March 2016


Approved by: Rob Gornall, Clinical Director, West Midlands Cancer Alliance and
Duncan Beardsmore, Chair of UGI Expert Advisory Group - 24 August 2017

Distribution: Upper GI Cancer EAG members
Trust Cancer Lead Clinicians
Cancer Trust Managers
Clinical Commissioning Groups within Cancer Alliance footprint

Version History:

Date	Version	Review
29 March 2016	V0.1	Reviewed and agreed at EAG March 2016
24 August 2017	V0.2	Minor amendments
5 October 2017	V1.0	
21 Aug 2019	V1.1	Updated to reflect the 2017 NICE Guidelines 2WW Referral indications, Ewen Griffiths, EAG Chair

Ideal Management Pathway for Oesophageal Carcinoma (exc EOC/HGD)



WMCN Oesophageal Carcinoma Pathway June 2016. These timings are currently aspirational and are an attempt to see what resources are required to comply with the new 2020 NHS cancer targets.